Immune-Onc Therapeutics
4 clinical trials · Sponsor
◉ Watch Immune-Onc Therapeutics
| Record | Firm | Date |
|---|---|---|
| Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors (NCT05508100) | Immune-Onc Therapeutics | 2022-09-09 |
| Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors (NCT05309187) | Immune-Onc Therapeutics | 2022-04-11 |
| First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors (NCT05054348) | Immune-Onc Therapeutics | 2021-09-30 |
| IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML (NCT04372433) | Immune-Onc Therapeutics | 2020-09-14 |
Track Immune-Onc Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.